These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 20883456

  • 1. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
    Blumberga G, Groes L, Dahl R.
    Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456
    [Abstract] [Full Text] [Related]

  • 2. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW.
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.
    JAMA; 2016 Apr 26; 315(16):1715-25. PubMed ID: 27115376
    [Abstract] [Full Text] [Related]

  • 4. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA, Casale TB, Nelson HS, Demoly P.
    J Allergy Clin Immunol; 2013 Dec 26; 132(6):1322-36. PubMed ID: 24139829
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH, Xu C, Liu L, Chai RN.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun 06; 56(6):774-783. PubMed ID: 35785859
    [Abstract] [Full Text] [Related]

  • 6. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C.
    Pediatr Allergy Immunol; 2007 Feb 06; 18(1):47-57. PubMed ID: 17295799
    [Abstract] [Full Text] [Related]

  • 7. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, Bahceciler NN, Barlan IB.
    J Investig Allergol Clin Immunol; 2015 Feb 06; 25(5):334-42. PubMed ID: 26727762
    [Abstract] [Full Text] [Related]

  • 8. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct 06; 29(10):679-87. PubMed ID: 17129496
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW, Virchow JC, Zieglmayer P, Ljørring C, Smith IM, Mosbech H.
    Expert Rev Clin Immunol; 2016 Aug 06; 12(8):805-15. PubMed ID: 27322777
    [Abstract] [Full Text] [Related]

  • 10. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children.
    Rosewich M, Arendt S, El Moussaoui S, Schulze J, Schubert R, Zielen S.
    Pediatr Allergy Immunol; 2013 Aug 06; 24(5):434-40. PubMed ID: 23578317
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB.
    Clin Exp Allergy; 2010 Jun 06; 40(6):922-32. PubMed ID: 20100188
    [Abstract] [Full Text] [Related]

  • 12. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO, Calderon MA, Durham SR.
    Expert Opin Biol Ther; 2013 Nov 06; 13(11):1543-56. PubMed ID: 24099116
    [Abstract] [Full Text] [Related]

  • 13. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Papadopoulos NG, Sokolowska M, Angier E, Fernandez-Rivas M, Pajno G, Pfaar O, Roberts GC, Ryan D, Sturm GJ, van Ree R, Varga EM, van Wijk RG, Yepes-Nuñez JJ, Jutel M.
    Allergy; 2019 May 06; 74(5):855-873. PubMed ID: 31095767
    [Abstract] [Full Text] [Related]

  • 14. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.
    Respir Med; 2013 Sep 06; 107(9):1322-9. PubMed ID: 23886432
    [Abstract] [Full Text] [Related]

  • 15. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
    Hesse L, van Ieperen N, Habraken C, Petersen AH, Korn S, Smilda T, Goedewaagen B, Ruiters MH, van der Graaf AC, Nawijn MC.
    Allergy; 2018 Apr 06; 73(4):862-874. PubMed ID: 29318623
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.
    J Allergy Clin Immunol; 2016 Dec 06; 138(6):1631-1638. PubMed ID: 27521719
    [Abstract] [Full Text] [Related]

  • 17. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J.
    J Allergy Clin Immunol; 2016 Feb 06; 137(2):444-451.e8. PubMed ID: 26292778
    [Abstract] [Full Text] [Related]

  • 18. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M, Klimek L, Richter H, Brüggenjürgen B, Vogelberg C.
    Allergy; 2024 Apr 06; 79(4):1042-1051. PubMed ID: 38429981
    [Abstract] [Full Text] [Related]

  • 19. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
    Yang Y, Ma D, Huang N, Li W, Jiang Q, Wang Y, Wang X, Yang L, Zhu R.
    Ital J Pediatr; 2021 Apr 23; 47(1):101. PubMed ID: 33892756
    [Abstract] [Full Text] [Related]

  • 20. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects.
    Chaoul N, Albanesi M, Giliberti L, Rossi MP, Nettis E, Di Bona D, Caiaffa MF, Macchia L.
    Int Arch Allergy Immunol; 2019 Apr 23; 179(1):37-42. PubMed ID: 30921804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.